Click here to listen to Charles's and other VIRAMUNE patients' inspiring stories.

References

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected  Adults and Adolescents.  AIDSinfo Web Site. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed November 30, 2007.

Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States - November 2, 2007. AIDSinfo Web site. Available at: http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?
MenuItem=Guidelines&Search=Off&GuidelineID=9&ClassID=2. Accessed November 30, 2007.

HIV and its treatment: What you should know. Available at: http://aidsinfo.nih.gov/contentfiles/HIVandItsTreatment_cbrochure_en.pdf. Accessed  November 30, 2007.

HIV and Depression. The National Women's Health Information Center Web site. Available at: http://forwoman.net/hiv/depress.cfm. Accessed November 30, 2007.

The HIV Life Cycle. The Body Web site. Available at: http://www.thebody.com/index/whatis/basics.html. Accessed November 30, 2007.

HIV Medicine 2006. HIV Medicine Web site. Available at: http://hivmedicine.com. Accessed November 30, 2007.

HIV Status and Disclosure: Choices & Consequences. SAT Web site. Available at: www.satregional.org/attachments/Publications/
Skills%20Training%20E/HIV%20Disclosure(pamphlet).pdf. Accessed on November 30, 2007.

Living with HIV/AIDS. The Body Web site. Available at: http://www.thebody.com/index/whatis/basics.html. Accessed November 30, 2007.

Hirsch MS, Brun-Vezinet F, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 Recommendations of an international AIDS society—USA Panel. CID. 2003;37:113-128.

St. John's Wort (Hypericum Perforatum). National Center for Complimentary and Alternative Medicine Web site. Available at: http://nccam.nih.gov/health/stjohnswort. Accessed November 30, 2007.

VIRAMUNE (nevirapine) Prescribing Information. Boehringer Ingelheim Pharmaceuticals, Inc.

Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: Recommendations of the HIV medicine association of the infectious diseases society of America. CID. 2004;39:609-629.

Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. Topics in HIV Medicine. 2005; 13:16-23.

Angelino AF, Treisman GJ. Management of psychiatric disorders in patients infected with human immunodeficiency virus. CID. 2001;33:847-856.

U.S. Department of Health and Human Services. Health Resources and Services Administration. Health Care and HIV: Nutritional guide for providers and clients. June 2002.

American Psychiatric Association, Office of HIV Psychiatry: Sleep disorders and HIV. Available at http:… Assessed November 27, 2007.

Reid S, Dwyer J. Insomnia in HIV infection: A systematic review of prevalence, correlates, and management. Psychosomatic Medicine. 2005;67:260-269.

Segerstrom SC, Miller GE. Psychological stress and the human immune system: A meta-analytic study of 30 years of inquiry. Psychological Bulletin. 2004;130:601-630.

Evans DL, Leserman J, Perkins DO, et al. Severe life stress as a predictor of early disease progression in HIV infection. Am J Psychiatry. 1997;154:630-634.

American Psychiatric Association. Practice Guideline for the treatment of patients with HIV/AIDs. November 2000.

American Foundation for AIDS Research: Facts about HIV/AIDS. Available at: http://www.thebody.com/amfar/ounce.html. Accessed October 12, 2007.

Meditation: Take a stress-reduction break wherever you are. Mayo Clinic Web site. Available at: http://www.mayoclinic.com/health/meditation/HQ01070. Accessed November 30, 2007.

Relaxation Techniques: Learn ways to calm your stress. Mayo Clinic Web site. Available at: http://www.mayoclinic.com/health/relaxation-technique/SR00007. Accessed November 30, 2007.

Wake Up to the Healing Properties of Sleep. The Body Web site. Available at: http://www.thebody.com/content/art32801.html. Accessed November 30, 2007.

Yoga: Minimize stress, maximize flexibility and even more. http://www.mayoclinic.com/health/yoga/CM00004. Mayo Clinic Web site. Available at: Accessed November 30, 2007.

You Can Quit Smoking. Agency for Health Research and Quality Web site. Available at: http://www.ahrq.gov/consumer/tobacco/quits.pdf. Accessed November 30, 2007.

Horwath E. Psychiatric and neuropsychiatric manifestations of HIV infection. JIAPAC. 2002;1(suppl 1):S1-S15.

Villes V, Spire B, Lewden C, et al, and the ANRS CO-8 APROCO-COPILOTE Study Group. The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice. Antivir Ther. 2007;12:1067-1074.

Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Pub Health. 2004;94:1133-1140.

Tucker JS, Burnam A, Sherbourne CD, Kung F-Y, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573-580.

DiMatteo MR, Lepper H, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med. 2000;160:2101-2107.

Bakken S, Holzemer WL, Brown M-A, et al. Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/AIDS. AIDS Patient Care STDS. 2000;14:189-197.

Halverson J, Chan C. Screening for psychiatric disorders in primary care. WMJ. 2004;103(6);46-51.

Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Disease Society of America. Clin Infect Dis. 2004;39:609-629.

HIV Medicine 2007. HIV Medicine Web site. Available at: http://www.hivmedicine.com/hivmedicine2007.pdf. Accessed January 15, 2008.

Hyperlipidemia Fact Sheet.  AIDSinfo Web Site. Available at: http://aidsinfo.nih.gov/contentfiles/Hyperlipidemia_FS_en.pdf. Accessed January 31, 2008.

Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Eng J Med. 2005;352:48-62.

The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.

van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1(1):64-74.

US Dept of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. US Dept of Health and Human Services. December 1, 2007; 1-113. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf Accessed January 15, 2008.

Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA. 2001;285:1466-1474.

Hader SL, Smith DK, Moore JS, Holmberg SD. HIV infection in women in the United States: status at the millennium. JAMA. 2001;285:1186-1192.

Lindsay MK, Grant J, Peterson HB, Willis S, Nelson P, Klein L. The impact of knowledge of human immunodeficiency virus serostatus on contraceptive choice and repeat pregnancy. Obstet Gynecol. 1995;85:675-679.

US Dept of Health and Human Services, Health Resources and Services Administration, HIV/AIDS bureau. A guide to the clinical care of women with HIV, 2005 edition. Available at: http://hab.hrsa.gov/publications/womencare05/

Living with HIV/AIDS. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/hiv/resources/brochures/print/livingwithhiv.htm. Accessed February 1, 2008.

INDICATION AND IMPORTANT SAFETY INFORMATION

VIRAMUNE is indicated for use in combination with other antiretroviral agents for the treatment of HIV infection.

VIRAMUNE does not cure HIV or AIDS, and has not been shown to reduce the risk of passing HIV to others through sexual contact or blood contamination.

VIRAMUNE can cause severe liver disease and skin reactions that can cause death. These reactions occur most often during the first 18 weeks of treatment, but can occur later. Ask your healthcare provider about how to recognize symptoms of skin and liver problems.

Stop taking VIRAMUNE if you have any of these reactions. Do not restart VIRAMUNE if you experience any of these reactions. Call your healthcare provider immediately if you have any of these reactions.

VIRAMUNE is only for people diagnosed with HIV. If you have not been diagnosed as HIV positive, then do not take VIRAMUNE.

Any patient can experience liver problems with VIRAMUNE, but women and patients who have higher CD4 counts when they begin VIRAMUNE treatment have a greater risk. If you are a woman with CD4+ >250 cells/mm3, or a man with CD4+ >400 cells/mm3, you should not begin taking VIRAMUNE unless you and your doctor have decided that the benefit of doing so outweighs the risk. Women, including pregnant women, with CD4+ cell counts >250 cells/mm3 are at the greatest risk.

Do not take VIRAMUNE if you have severe liver problems.

The dose of VIRAMUNE for adults is one 200-mg tablet daily for the first 14 days, followed by one 200-mg tablet twice daily. VIRAMUNE is always taken with other anti-HIV medications. The 14-day lead-in period is important because it can help reduce your chances of getting a potentially serious skin rash. If you have a skin rash during the first 14 days, immediately contact your doctor and do not increase your VIRAMUNE dose to twice a day. The total duration of the once daily lead-in dosing period should not exceed 28 days, at which point an alternative regimen may need to be started.

Other side effects that patients have experienced include nausea, fatigue, fever, headache, vomiting, diarrhea, abdominal pain, and myalgia. Changes in body fat may occur in patients receiving antiretroviral therapy. Immune reconstitution syndrome has been reported in patients treated with combination ARV therapy.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATION AND IMPORTANT SAFETY INFORMATION

VIRAMUNE is indicated for use in combination with other antiretroviral agents for the treatment of HIV infection.

VIRAMUNE does not cure HIV or AIDS, and has not been shown to reduce the risk of passing HIV to others through sexual contact or blood contamination.

VIRAMUNE can cause severe liver disease and skin reactions that can cause death. These reactions occur most often during the first 18 weeks of treatment, but can occur later. Ask your healthcare provider about how to recognize symptoms of skin and liver problems.

Stop taking VIRAMUNE if you have any of these reactions. Do not restart VIRAMUNE if you experience any of these reactions. Call your healthcare provider immediately if you have any of these reactions.

VIRAMUNE is only for people diagnosed with HIV. If you have not been diagnosed as HIV positive, then do not take VIRAMUNE.

Any patient can experience liver problems with VIRAMUNE, but women and patients who have higher CD4 counts when they begin VIRAMUNE treatment have a greater risk. If you are a woman with CD4+ >250 cells/mm3, or a man with CD4+ >400 cells/mm3, you should not begin taking VIRAMUNE unless you and your doctor have decided that the benefit of doing so outweighs the risk. Women, including pregnant women, with CD4+ cell counts >250 cells/mm3 are at the greatest risk.

Do not take VIRAMUNE if you have severe liver problems.

The dose of VIRAMUNE for adults is one 200-mg tablet daily for the first 14 days, followed by one 200-mg tablet twice daily. VIRAMUNE is always taken with other anti-HIV medications. The 14-day lead-in period is important because it can help reduce your chances of getting a potentially serious skin rash. If you have a skin rash during the first 14 days, immediately contact your doctor and do not increase your VIRAMUNE dose to twice a day. The total duration of the once daily lead-in dosing period should not exceed 28 days, at which point an alternative regimen may need to be started.

Other side effects that patients have experienced include nausea, fatigue, fever, headache, vomiting, diarrhea, abdominal pain, and myalgia. Changes in body fat may occur in patients receiving antiretroviral therapy. Immune reconstitution syndrome has been reported in patients treated with combination ARV therapy.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information, including boxed WARNING and Medication Guide, for VIRAMUNE.